• Abdallah R Dalabih, Steven A Bondi, Zena L Harris, Benjamin R Saville, Wenli Wang, and Donald H Arnold.
• University of Missouri School of Medicine, Department of Child Health, Division of Pediatric Critical Care, 404 Keene St, Columbia, MO 65201, USA. Electronic address: dalabiha@missouri.edu.
• Pulm Pharmacol Ther. 2014 Feb 1;27(1):57-61.

IntroductionThe role of aminophylline in the treatment of severe acute asthma in the pediatric critical care unit (PCCU) is not clear. We sought to examine the association of aminophylline treatment with PCCU length of stay and time to symptom improvement.Material And MethodsPatients with severe acute asthma who were admitted to our PCCU and received aminophylline infusion were retrospectively compared with similar patients who did not receive aminophylline. The primary outcome measure was functional length of stay (i.e. time to which patients could be transferred to a general pediatric ward bed). A secondary outcome was time to symptom improvement.ResultsAdjusted functional length of stay was longer for subjects who received aminophylline (n = 49) than for the patients who did not (n = 47) (hazard ratio 0.396, p < 0.001), as well as the time for symptom improvement (hazard ratio 0.359, p < 0.001). In the group of subjects receiving aminophylline, those with a serum theophylline level ≥ 10 mcg/ml (therapeutic) (n = 31) had longer functional length of stay (hazard ratio 0.457, p = 0.0225) and time to symptom improvement (hazard ratio 0.403, p = 0.0085) than those with levels < 10 mcg/ml (sub-therapeutic) (n = 18).ConclusionsThe addition of aminophylline to therapy with corticosteroids and inhaled β-agonists was associated with statistically and clinically significant increases in functional length of stay and time to symptom improvement in the PCCU. This potential morbidity supports the National Asthma Education and Prevention Program guideline proscribing aminophylline use in acute asthma.Copyright © 2013 Elsevier Ltd. All rights reserved.

49 keywords...

hide…